Faktor-Faktor yang Berhubungan dengan Kualitas Hidup pada Pasien Pasca Tuberkulosis

Siti Khotimah; Ana Majdawati; Wawan Ramdani

doi:10.32382/medkes.v20i2.1895

Authors

Siti Khotimah Department of Physiotherapy, Faculty of Health Sciences, Universitas Aisyiyah, Yogyakarta, Indonesia
Ana Majdawati Radiology Department, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Yogyakarta, Bantul, Indonesia
Wawan Febri Ramdani Department of Nursing, Faculty of Health Sciences, Universitas Aisyiyah, Yogyakarta, Indonesia

DOI:

https://doi.org/10.32382/medkes.v20i2.1895

Keywords:

Post-tuberculosis, quality of life, fatigue, SGRQ, post-tuberculosis lung disease

Abstract

Background: Tuberculosis (TB) remains a significant global health problem. Although bacteriological cure can be achieved, many post-tuberculosis patients experience persistent residual symptoms and a decline in quality of life. Objective: This study aimed to identify factors associated with quality of life among post-tuberculosis patients. A cross-sectional study was conducted among 54 post-tuberculosis patients in Yogyakarta, Indonesia. Quality of life was assessed using the St. George's Respiratory Questionnaire (SGRQ). Bivariate and multivariate analyses (linear regression) were performed to identify factors associated with quality of life. Results: The median SGRQ score was 42.8 (IQR: 12.5–68.3). Fatigue was reported in 20.4% of participants. Multivariate analysis showed that fatigue was the dominant independent predictor (B=28.5, β=0.412, p=0.008), explaining 38.0% of the variance in SGRQ scores.. Conclusion: Fatigue is the dominant independent predictor of impaired quality of life in post-tuberculosis patients. Comprehensive care programs that include fatigue assessment and management are needed to improve the quality of life of TB survivors.

References

Maulana S, Lutfian L, Wardika IJ, et al. Emerging Research Trends on Medication Adherence in Tuberculosis Treatment: A Bibliometric Study of Research Between 2015 and 2024 to Inform Future Research Trajectory. Patient Preference and Adherence .Dove Medical Press Ltd. 2025;19:2213-2226. doi:10.2147/PPA.S520341

World Health Organization (WHO). 2024 Global Tuberculosis Report.; 2024. Accessed October 22, 2025. http://iris.who.int/server/api/core/bitstreams/7292c91e-ffb0-4cef-ac39-0200f06961ea/content

Lopes SR, Marçal M, Fernandes N, et al. Update in tuberculosis treatment: a scoping review of current practices. Breathe.European Respiratory Society. 2025;21(1). doi:10.1183/20734735.0232-2024

Allwood BW, Byrne A, Meghji J, Rachow A, Van Der Zalm MM, Schoch OD. Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge. Respiration.S. Karger AG. 2021;100(8):751-763. doi:10.1159/000512531

Allwood BW, Van Der Zalm MM, Amaral AFS, et al. Post-tuberculosis lung health: Perspectives from the First International Symposium. In: International Journal of Tuberculosis and Lung Disease. Vol 24. International Union Against Tuberculosis and Lung Disease (The Union); 2020:820-828. doi:10.5588/ijtld.20.0067

Guglielmetti L, Panda S, Abubakirov A, Salahuddin N, Perrin C, Mitnick CD. Equitable, personalised medicine for tuberculosis: treating patients, not diseases. Lancet Respir Med.Elsevier Ltd. 2025;13(5):382-385. doi:10.1016/S2213-2600(25)00080-3

Auld SC, Barczak AK, Bishai W, et al. Pathogenesis of Post-Tuberculosis Lung Disease Defining Knowledge Gaps and Research Priorities at the Second International Post-Tuberculosis Symposium. Am J Respir Crit Care Med.American Thoracic Society. 2024;210(8):979-993. doi:10.1164/rccm.202402-0374SO

Ehlers S, Schaible UE. The granuloma in tuberculosis: Dynamics of a host-pathogen collusion. Front Immunol. 2012;3(JAN). doi:10.3389/fimmu.2012.00411

Liu Y, Sun W, Shen N, et al. Network pharmacology and molecular docking combined with widely targeted metabolomics to elucidate the potential compounds and targets of Euphorbia helioscopia seeds for the treatment of pulmonary fibrosis. Comput Biol Med. 2023;160. doi:10.1016/j.compbiomed.2023.107007

Gai X, Allwood B, Sun Y. Post-tuberculosis lung disease and chronic obstructive pulmonary disease. Chin Med J (Engl).Lippincott Williams and Wilkins. 2023;136(16):1923-1928. doi:10.1097/CM9.0000000000002771

Meghji J, Auld SC, Bisson GP, et al. Post-tuberculosis lung disease: towards prevention, diagnosis, and care. Lancet Respir Med. 2025;13(5):460-472. doi:https://doi.org/10.1016/S2213-2600(24)00429-6

Talhar SS, Ambulkar PS, Sontakke BR, et al. Oxidative stress and its impact on mitochondrial DNA in pulmonary tuberculosis patients- a pilot study. Indian Journal of Tuberculosis. 2019;66(2):227-233. doi:https://doi.org/10.1016/j.ijtb.2019.03.001

Zhao X, Lv P, Cai Z, et al. Unveiling the role of NAD glycohydrolase CD38 in aging and age-related diseases: insights from bibliometric analysis and comprehensive review. Front Immunol.Frontiers Media SA. 2025;16. doi:10.3389/fimmu.2025.1579924

Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-1139. doi:10.1016/j.cmet.2016.05.006

Xie N, Zhang L, Gao W, et al. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther.Springer Nature. 2020;5(1). doi:10.1038/s41392-020-00311-7

Kim S, Pelissari DM, Harada LO, et al. Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil. Clinical Infectious Diseases. Published online April 18, 2025. doi:10.1093/cid/ciaf206

Meghji J, Auld SC, Bisson GP, et al. Post-tuberculosis lung disease: towards prevention, diagnosis, and care. Lancet Respir Med. 2025;13(5):460-472. doi:10.1016/S2213-2600(24)00429-6

Smirnova N, Bryan CS, Salindri AD, et al. Cavitary lung lesions and quality of life after TB. International Journal of Tuberculosis and Lung Disease.International Union Against Tuberculosis and Lung Disease (The Union). 2024;28(10):505-507. doi:10.5588/ijtld.23.0590

Zhou A, Ni J, Xu Z, et al. Metabolomics specificity of tuberculosis plasma revealed by 1H NMR spectroscopy. Tuberculosis. 2015;95(3):294-302. doi:10.1016/j.tube.2015.02.038

Sharma R, Hartman TE, Beites T, et al. Metabolically distinct roles of NAD synthetase and NAD kinase definethe essentiality of NAD and NADP in Mycobacterium tuberculosis. mBio. 2023;14(4). doi:10.1128/mbio.00340-23

Abdellatif M, Trummer-Herbst V, Koser F, et al. Nicotinamide forthe treatment of heart failure with preserved ejection fraction. Sci Transl Med. 2021;13(580). doi:10.1126/scitranslmed.abd7064

Liu QY, Han F, Pan LP, Jia HY, Li Q, Zhang Z De. Inflammation responses in patients with pulmonary tuberculosis in an intensive care unit. Exp Ther Med. 2018;15(3):2719-2726. doi:10.3892/etm.2018.5775

Boni FG, Hamdi I, Koundi LM, Shrestha K, Xie J. Cytokine storm in tuberculosis and IL-6 involvement. Infection, Genetics and Evolution.Elsevier B.V. 2022;97. doi:10.1016/j.meegid.2021.105166

Yang TY, Lin CL, Yao WC, et al. How mycobacterium tuberculosis infection could lead to the increasing risks of chronic fatigue syndrome and the potential immunological effects: a population-based retrospective cohort study. J Transl Med. 2022;20(1). doi:10.1186/s12967-022-03301-1

Choi CJ, Choi WS, Kim CM, Lee SY, Kim KS. Risk of Sarcopenia and Osteoporosis in Male Tuberculosis Survivors: Korea National Health and Nutrition Examination Survey. Sci Rep. 2017;7(1). doi:10.1038/s41598-017-12419-y

Crescioli C. Targeting age-dependent functional and metabolic decline of human skeletal muscle: The geroprotective role of exercise, myokine IL-6, and vitamin D. Int J Mol Sci.MDPI AG. 2020;21(3). doi:10.3390/ijms21031010

Abdellatif M, Sedej S, Kroemer G. NAD+ Metabolism in Cardiac Health, Aging, and Disease. Circulation.Lippincott Williams and Wilkins. 2021;144(22):1795-1817. doi:10.1161/CIRCULATIONAHA.121.056589

Liu F, Yin X, Jiang W. Comprehensive Review and Meta-Analysis of Psychological and Pharmacological Treatment for Intermittent Explosive Disorder: Insights From Both Case Studies and Randomized Controlled Trials. Clin Psychol Psychother.John Wiley and Sons Ltd. 2025;32(1). doi:10.1002/cpp.70016

Gupta MB, Bagri S, Garg A, Singh DK, Choudhary P, Sahni S. Pulmonary function in cured pulmonary tuberculosis cases. Indian Journal of Tuberculosis. 2022;69(4):535-538. doi:https://doi.org/10.1016/j.ijtb.2021.08.024